Exchange Traded Concepts LLC Sells 984 Shares of BioNTech SE (NASDAQ:BNTX)

Exchange Traded Concepts LLC lowered its stake in BioNTech SE (NASDAQ:BNTX) by 42.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,356 shares of the company’s stock after selling 984 shares during the quarter. Exchange Traded Concepts LLC’s holdings in BioNTech were worth $161,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BNTX. Candriam S.C.A. lifted its stake in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the period. Point72 Asset Management L.P. increased its stake in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares during the last quarter. SG Americas Securities LLC raised its position in shares of BioNTech by 610.5% in the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after acquiring an additional 60,270 shares during the period. Acadian Asset Management LLC boosted its stake in BioNTech by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock worth $10,275,000 after acquiring an additional 37,792 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in BioNTech during the second quarter valued at approximately $2,892,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BNTX. Deutsche Bank Aktiengesellschaft increased their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. HSBC lifted their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, UBS Group boosted their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.54.

BioNTech Trading Down 0.2 %

BioNTech stock opened at $111.58 on Tuesday. The company has a market cap of $26.53 billion, a price-to-earnings ratio of 223.16 and a beta of 0.24. The firm has a 50-day moving average of $104.56 and a 200-day moving average of $94.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period last year, the company posted ($0.86) earnings per share. On average, equities analysts expect that BioNTech SE will post -3.04 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.